Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Keen, Susan MD
  2. Craven, Kay MPH, RDN, LDN, CDE
  3. Kolasa, Kathryn M. PhD, RDN, LDN

Abstract

The number of Americans with type 2 diabetes has grown from an estimated 20.8 million in 2005 to 29.1 million in 2012 or 9.3% of the population (http://www.diabetes.org/diabetes-basis/statistics). Medications for the treatment of type 2 diabetes targeting incretin hormones for improved glycemic control have emerged as favorable second-line additions to metformin and lifestyle changes. In this article, we discuss the benefits of using glucagon-like peptide 1 receptor agonist medications and dipeptidyl peptidase 4 inhibitors along with their implications for weight and dietary management of type 2 diabetes.